WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2015089389) PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2015/089389    International Application No.:    PCT/US2014/069997
Publication Date: 18.06.2015 International Filing Date: 12.12.2014
IPC:
C07F 15/00 (2006.01), A61K 47/48 (2006.01), A61K 31/282 (2006.01), A61P 35/00 (2006.01), A61P 31/00 (2006.01)
Applicants: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. [US/US]; Boyd Graduate Studies Research Center Athens, GA 30602-7411 (US)
Inventors: DHAR, Shanta; (US).
PATHAK, Rakesh; (US)
Agent: CAMPBELL, Keith, M.; (US)
Priority Data:
61/915,110 12.12.2013 US
61/976,559 08.04.2014 US
Title (EN) PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR
(FR) PRODROGUE POUR LIBÉRATION DE CISPLATINE ET D'UN INHIBITEUR DE CYCLOOXYGÉNASE
Abstract: front page image
(EN)Pt(IV) prodrugs include one or more conjugated cyclooxygenase inhibitor. Reduction of Pt(IV) to Pt(II) can result cisplatin and a cyclooxygenase inhibitor. For proof of concept, a Pt(IV) prodrug that can produce cisplatin and aspirin, Platin-A, was synthesized. Platin-A exhibited excellent anticancer and anti-inflammatory properties, which were better than the combination of free formulation of cisplatin and aspirin.
(FR)Les prodrogues au Pt(IV) comprennent un ou plusieurs inhibiteurs de cyclooxygénase conjugués. La réduction du Pt(IV) en Pt(II) peut conduire au cisplatine et à un inhibiteur de cyclooxygénase. Comme preuve du concept, une prodrogue d'un Pt(IV) a été synthétisée, qui peut produire du cisplatine et de l'aspirine, le Platine-A. Le Platine-A a présenté d'excellentes propriétés anticancéreuses et anti-inflammatoires, qui ont été meilleures que l'association de la formulation libre de cisplatine et d'aspirine.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)